We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Corgenix Medical Corporation has released for international sale its newest diagnostic product to be used in the fight against cardiovascular disease. The Company's AspirinWorks(R) Test Kit was launched at the 52nd Annual Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, held June 28 through July 1, 2006, in Oslo, Norway.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), today announced the signing of an agreement with BioReference Laboratories of Elmwood Park, NJ for BD to supply BRLI with instrumentation and reagents for testing and diagnosis of sexually transmitted infections (STI).
Zimmer Holdings, Inc., a leader in the orthopaedics industry, announced today that it has received approval of its Premarket Approval Application
(PMA) from the United States Food and Drug Administration (FDA) to market the Trilogy AB(R) Ceramic-on-Ceramic Acetabular System.
A bill recently approved by a House panel has raised concerns in the medical technology industry that research programs sponsored by the National Institutes of Health (NIH) will suffer funding cuts.
An initial round of trade negotiations between the U.S. and South Korea in early June has "significant implications" for the device and diagnostics industry, AdvaMed said June 27.
Epigenomics AG. a molecular diagnostics company developing tests based on DNA methylation, is presenting new clinical data on its colorectal cancer early detection marker in blood. The results indicate that, combined with a second proprietary marker, the test is also able to detect most polyps without many false positive results.
Wednesday morning, Medtronic Inc., a manufacturer of medical devices, revealed it received approval from the U.S. Food and Drug Administration or FDA for its InterStim II System for the treatment of intractable cases of overactive bladder and urinary retention.
Lumen Biomedical Inc. said Wednesday it has received clearance from the U.S. Food and Drug Administration to market its first product in the United States.
CAS Medical Systems, Inc., a medical device company focused on innovative non-invasive vital signs monitoring, today announced that it has been awarded two United States Patents for technology used in its FORE-SIGHT Cerebral Oximeter, which is scheduled for commercial release in late 2006.